Corvus Pharmaceuticals Inc (CRVS) Given Average Rating of “Buy” by Brokerages

Shares of Corvus Pharmaceuticals Inc (NASDAQ:CRVS) have been assigned a consensus rating of “Buy” from the seven ratings firms that are covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $13.58.

Several analysts have recently issued reports on the stock. BidaskClub cut shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 21st. Credit Suisse Group raised shares of Corvus Pharmaceuticals from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $11.00 to $15.00 in a research report on Wednesday, August 15th. Zacks Investment Research raised shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $8.75 price objective on the stock in a research report on Wednesday, November 7th. Finally, Cowen reissued a “buy” rating on shares of Corvus Pharmaceuticals in a research report on Friday, November 2nd.

Institutional investors have recently bought and sold shares of the stock. Trexquant Investment LP purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $107,000. Rhumbline Advisers purchased a new stake in Corvus Pharmaceuticals in the 2nd quarter worth about $147,000. Citadel Advisors LLC purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $182,000. Acadian Asset Management LLC raised its position in Corvus Pharmaceuticals by 129.3% in the 2nd quarter. Acadian Asset Management LLC now owns 21,494 shares of the company’s stock worth $236,000 after purchasing an additional 12,119 shares during the period. Finally, Credit Suisse AG purchased a new stake in Corvus Pharmaceuticals in the 3rd quarter worth about $194,000. 87.42% of the stock is currently owned by institutional investors.

Shares of NASDAQ CRVS traded down $0.05 during mid-day trading on Monday, hitting $5.89. 60,393 shares of the company’s stock traded hands, compared to its average volume of 72,519. The stock has a market capitalization of $173.94 million, a price-to-earnings ratio of -2.17 and a beta of -0.68. Corvus Pharmaceuticals has a 1 year low of $5.66 and a 1 year high of $13.91.

Corvus Pharmaceuticals (NASDAQ:CRVS) last announced its earnings results on Thursday, November 1st. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.12. On average, equities analysts forecast that Corvus Pharmaceuticals will post -1.77 EPS for the current fiscal year.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.

Recommended Story: Balance Sheet

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply